hit counter
Adaptimmune Therapeutics plc (ADAP) Stock News Sentiment & Price - Sentifly
ADAP - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Adaptimmune Therapeutics plc (ADAP)

United Kingdom
Biotechnology
NASDAQ
ADAP Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ADAP Latest news
Benzinga
Positive
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
2021-11-11 14:17

Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society annual meeting. The Company says that the trial will meet its primary endpoint for efficacy, and the data will be used to support marketing application filing for afami-cel next year.

GlobeNewsWire
Neutral
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
2021-11-11 09:00

- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year -

Seeking Alpha
Neutral
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript
2021-11-04 14:47

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript

The Motley Fool
Positive
2 Biotech Companies That Might Be on Pfizer's Radar Right Now
2021-11-04 10:00

These two small-cap cancer companies would be a perfect fit for Pfizer.

Benzinga
Neutral
Adaptimmune Therapeutics: Q3 Earnings Insights
2021-11-04 08:03

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

GlobeNewsWire
Neutral
Adaptimmune Reports Third Quarter Financial Results and Business Update
2021-11-04 07:30

- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment -

GlobeNewsWire
Neutral
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
2021-10-21 08:00

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) that same day (details below).

The Motley Fool
Positive
2 Top Healthcare Stocks That Could Be Bought Out in 2022
2021-10-16 07:00

These two novel-drug makers could be top takeover targets next year.

GlobeNewsWire
Neutral
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
2021-10-05 08:00

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -

Seeking Alpha
Positive
Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
2021-09-29 10:18

Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.

Loading more news...